Patent SG-11201901468S-A (SG)
Title: Antibodies with reduced binding to process impurities
Inventor: BOSTEELS HELLA
IPC: C07K16/00
Filed: 2017-10-03
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 12 April 2018 (12.04.2018) WIP0 1 PCT ill~~~~~~~~ 011101010VIIIOH olo olioluniom Eno iflo oimIE (10) International Publication Number WO 2018/065389 Al (51) International Patent Classification: C07K 16/00 (2006.01) (21) International Application Number: PCT/EP2017/075038 (22) International Filing Date: 03 October 2017 (03.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/404,849 06 October 2016 (06.10.2016) US (71) Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED [GB/GB]; 980 Great West Road, Brentford Middlesex TW8 9GS (GB). (72) Inventors: BOSTEELS, Hella; GlaxoSmithKline, Gun- nels Wood Road, Stevenage Hertfordshire SG1 2NY (GB). CHEN, Shugui; GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406 (US). FAR- ROW, Kayeleigh; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB). KUCIA-TRAN, Richard; GlaxoSmithKline, Gunnels Wood Road, Steve- nage Hertfordshire SG1 2NY (GB). LEWIS, William John Kenneth; GlaxoSmithKline, Gunnels Wood Road, Steve- nage Hertfordshire SG1 2NY (GB). THOMSON, An- drew S.; GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406 (US). UDEN, Mark; Glax- oSmithKline, Gunnels Wood Road, Stevenage Hertford- shire SG1 2NY (GB). (74) Agent: BHOGAL, Jasber Kaur; GlaxoSmithKline, Glob- al Patents (CN925.1), 980 Great West Road, Brentford Mid- dlesex TW8 9GS (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) 1-1 C/1 00 \"\") (54) Title: ANTIBODIES WITH REDUCED BINDING TO PROCESS IMPURITIES 1 1 (57) : The present invention relates to variant antibodies and methods of generating said antibodies with a reduced level of binding to process impurities. In particular, the invention describes variant IgG4 antibodies which have been modified in the heavy chain constant region at any one or a combination of amino acids in the region between Kabat residues 203 and 256, wherein the variant IgG4 antibody has a reduced level of binding to host cell protein (HCP), compared to an unmodified IgG4 antibody. The invention also N relates to compositions comprising said variant IgG4 antibodies.